U.S. markets closed

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.9331-0.0469 (-1.18%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close3.9800
Bid3.2000 x 1100
Ask4.0000 x 900
Day's Range3.4924 - 3.9331
52 Week Range3.4920 - 15.7800
Avg. Volume6,584
Market Cap155.018M
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-1.3330
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inventiva S.A. - American Depos
    ITOS: What does Argus have to say about ITOS?ITEOS THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Benzinga

    Inventiva's NASH Pact In China Represents 'Financially Prudent Pathway,' Says This Analyst

    Last week, Inventiva (NASDAQ: IVA) announced a licensing and collaboration agreement with Sino Biopharm's subsidiary Chia Tai-Tianqing Pharmaceutical Group (CTTQ) to develop and commercialize lanifibranor in Greater China. Regardless of CTTQ's decision on lanifibranor's clinical development pathway in China, HC Wainwright notes that Sino Biopharm is a vertically-integrated company with substantial R&D, manufacturing, sales, and marketing capability. The analyst regards the collaboration as a fin

  • Benzinga

    Inventiva Inks Licensing Pact With China-Based Sino Biopharm For NASH Candidate In Greater China

    Inventiva (NASDAQ: IVA) and Chia Tai-Tianqing Pharmaceutical Group Co Ltd, a Sino Biopharm subsidiary, have entered into a licensing and collaboration agreement to develop and commercialize lanifibranor for non-alcoholic steatohepatitis (NASH) and potentially other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan. Inventiva will receive an upfront payment of $12 million, and $5 million are also expected in the short term if certain clinical milestones are met. Inventiva has the

  • GlobeNewswire

    Inventiva reports its 2022 first-half financial results and provides a corporate update

    Cash position1 at €87.2 million as of June 30, 2022, compared to €95.4 million as of December 31, 2021 Receipt of a €4 million milestone payment from Inventiva’s partner AbbVie for cedirogant Phase IIb clinical trial initiation accounted for in 2021 revenues and H1 2022 cash flowInventiva entered into a credit facility for up to €50 million, subject to conditions, and a related warrant agreement with the European Investment Bank (EIB)2Inventiva raised approximately €14.7 million through a combin